Trial Profile

A Phase I Study to Assess the Tolerability, Safety and Efficacy of Fluzoparib in Combination With mFOLFIRINOX as Neoadjuvant and Adjuvant Therapy in Patients With Resectable Pancreatic Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Fuzuloparib (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

04 Jun 2024 Results (As of Oct 31, 2023, n=15) assessing safety and efficacy of Perioperative fuzuloparib plus mFOLFIRINOX for resectable pancreatic adenocarcinoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology
21 Dec 2020 Status changed from not yet recruiting to recruiting.
09 Aug 2020 Planned initiation date changed from 1 Sep 2020 to 1 Nov 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com